\u201cBRAF-inhibitors provide very different clinical outcomes,\u201d said Dr. Scott Kopetz, a Professor and Associate Vice President for Translational Integration at The University of Texas MD Anderson Cancer Center. \u201cThey work amazingly well in melanoma, for example, but are less effective in colorectal cancer.\u201d<\/p>\n
\u201cBRAF [in colorectal cancer] is that odd uncle who doesn\u2019t behave like the rest of the family. The black sheep. Is he even related? The usual rules don\u2019t apply.\u201d<\/p>\n
Dr. Kopetz and his team\u2019s most recent studies of this black sheep are now moving from research in mice to clinical trials in humans. These trials were approved by the National Cancer Institute in October and will launch in early 2024. <\/strong><\/p>\n The GI Research Foundation helped support the work with mice models, along with several other aspects of the team\u2019s BRAF-related research. The $3.5 million grant is part of the foundation\u2019s massive CA CURE initiative.<\/p>\n \u201cLast year, we were able to deliver more than $18 million to researchers across the country to improve diagnostics and develop immunotherapies and personalized vaccines in gastrointestinal cancers through CA CURE,\u201d said Katie Chudnovsky, chair of the GI Research Foundation\u2019s Board of Directors. \u201cPatients need treatments like those being developed by Dr. Kopetz \u2013 so very urgently \u2013 and we are thrilled to see this team\u2019s work moving to clinical trials so quickly.\u201d<\/p>\n BRAF-mutated colorectal cancer comes with a \u201cdismal prognosis,\u201d according to research in the International Journal of Molecular Sciences, and the median patient survives less than a year.<\/p>\n This new form of treatment for BRAF-mutated colorectal cancer relies on what Kopetz called a \u201ctwo-hit hypothesis.\u201d That is, these cancers are caused by the combination of mutations in the BRAF gene and epigenetic dysregulation.<\/strong> Epigenetic dysregulation refers to the fact that behaviors and environment can impact how a person\u2019s genes behave.<\/p>\n Here, researchers have found that a mutation to the BRAF gene changes the production of proteins that cause healthy cells to grow into cancerous tumors. Other forms of BRAF-mutated cancer respond well to BRAF-inhibitor immunotherapy that can halt the production of those proteins. <\/p>\n In BRAF-mutated colorectal cancer, however, another piece of DNA is unable to express itself entirely. Those genes typically create natural tumor suppressors that fight early cancer growth. Carbon molecules called methyl groups attach themselves to the DNA and prevent the DNA from building cancer-suppressing proteins. That \u201cmethylation\u201d is the epigenetic dysregulation in this case, likely caused by inflammation, diet, or external environmental factors.<\/p>\n If doctors can stop the proteins that cause cancer and<\/i> stop the bromodomains, they might be able to produce a one-two punch to combat their double hit hypothesis. The treatment would slow BRAF-mutated colorectal cancer growth and encourage natural cancer suppressors.<\/p>\n That idea will be tested in the human trials that were recently approved by the National Cancer Institute. A BRAF-inhibitor, an EGFR-inhibitor, and a bromodomain-inhibitor will be administered to patients. This combined treatment was developed by Kopetz and his colleague Dr. Kunal Rai, an Associate Professor of Genomic Medicine at MD Anderson.<\/p>\n The research moved from the GI Research Foundation-funded mouse models to human trials exceptionally quickly<\/strong>, according to Kopetz.<\/p>\n \u201cIt\u2019s rare for the pieces to come together like this,\u201d he said. \u201cLots of times, this would be two years of work to get the human trials up and running. But we were able to show how clearly this approach worked in multiple mouse models and that really sped things up.\u201d<\/p>\n Other funding from the GI Research Foundation will help speed things up even further. \u201cThe new technologies and techniques that Dr. Kopetz and his team are exploring will give them the ability to innovate that much faster. It provides the entire community with the means to gather high-quality data more quickly and get it into trials and ultimately into the clinic,\u201d said Dr. David Rubin. Rubin is the Joseph B. Kirsner Professor of Medicine and Chief of the Section of Gastroenterology, Hepatology and Nutrition at University of Chicago Medicine. He is also GI Research Foundation\u2019s Senior Scientific Advisor. <\/p>\n \u201cThe GI Research Foundation has a legacy of funding high risk-high reward and innovative science, and doing so efficiently and extraordinarily effectively. Kopetz and his colleagues were recipients of a dedicated campaign that we launched in 2022 to tackle the most difficult challenges of colorectal cancer.\u201d<\/p>\n \u201cSupport from the GI Research Foundation allows us to accelerate our work and try some out of the box stuff,\u201d Kopetz said. \u201cWe have amazing animal models, but there\u2019s no substitute for understanding cancer and treatments with the patients themselves. We want to develop the tools we need so we can learn as much as possible from them and help them as much and as quickly as we can.\u201d<\/p>\n About the GI Research Foundation<\/strong><\/p>\n The GI Research Foundation was founded in 1961 by grateful patients and friends of the late Dr. Joseph B. Kirsner, a pioneer in gastroenterology who devoted his life to medicine, teaching, and patient care. Today, the University of Chicago Medicine\u2019s Digestive Diseases Center, which is supported by the foundation, is internationally recognized for research-driven medicine and its team of highly specialized physicians. For more information, see: https:\/\/giresearchfoundation.org\/<\/a><\/p>\n About the University of Chicago Digestive Diseases Center<\/strong><\/p>\n The Digestive Diseases Center at the University of Chicago Medicine is a collaborative, multidisciplinary network of physicians, researchers and affiliated health professionals who share a legacy of innovation and a common purpose: to improve the lives of patients who suffer from digestive diseases. For more information, see: https:\/\/www.uchicagomedicine.org\/conditions-services\/digestive-diseases<\/a><\/p>\n\n \n Contact Information:<\/strong>\n\n With $3.5 million in funding from the GI Research Foundation, a team at the MD Anderson Cancer Center explores a one-two punch to combat BRAF-mutated colorectal cancer and its \u201cdismal prognosis.\u201d<\/b><\/p>\n \u201cBRAF-inhibitors provide very different clinical outcomes,\u201d said Dr. Scott Kopetz, a Professor and Associate Vice President for Translational Integration at The University of Texas\u00a0MD Anderson Cancer Center. \u201cThey work amazingly well in melanoma, for example, but are less effective in colorectal cancer.\u201d<\/p>\n \u201cBRAF [in colorectal cancer] is that odd uncle who doesn\u2019t behave like the rest of the family. The black sheep. Is he even related? The usual rules don\u2019t apply.\u201d<\/p>\n Dr. Kopetz and his team\u2019s most recent studies of this black sheep are now moving from research in mice to clinical trials in humans. These trials were approved by the National Cancer Institute in October and will launch in early 2024.\u00a0<\/strong><\/p>\n The GI Research Foundation helped support the work with mice models, along with several other aspects of the team\u2019s BRAF-related research. The $3.5 million grant is part of the foundation\u2019s massive CA CURE initiative.<\/p>\n \u201cLast year, we were able to deliver more than $18 million to researchers across the country to improve diagnostics and develop immunotherapies and personalized vaccines in gastrointestinal cancers through CA CURE,\u201d said Katie Chudnovsky, chair of the GI Research Foundation\u2019s Board of Directors. \u201cPatients need treatments like those being developed by Dr. Kopetz \u2013 so very urgently \u2013 and we are thrilled to see this team\u2019s work moving to clinical trials so quickly.\u201d<\/p>\n BRAF-mutated colorectal cancer comes with a \u201cdismal prognosis,\u201d according to research in the International Journal of Molecular Sciences, and the median patient survives less than a year.<\/p>\n This new form of treatment for BRAF-mutated colorectal cancer relies on what Kopetz called a \u201ctwo-hit hypothesis.\u201d That is,\u00a0these cancers are caused by the combination of mutations in the BRAF gene and epigenetic dysregulation.<\/strong> Epigenetic dysregulation refers to the fact that behaviors and environment can impact how a person\u2019s genes behave.<\/p>\n Here, researchers have found that a mutation to the BRAF gene changes the production of proteins that cause healthy cells to grow into cancerous tumors. Other forms of BRAF-mutated cancer respond well to BRAF-inhibitor immunotherapy that can halt the production of those proteins.\u00a0<\/p>\n In BRAF-mutated colorectal cancer, however, another piece of DNA is unable to express itself entirely. Those genes typically create natural tumor suppressors that fight early cancer growth. Carbon molecules called methyl groups attach themselves to the DNA and prevent the DNA from building cancer-suppressing proteins. That \u201cmethylation\u201d is the epigenetic dysregulation in this case, likely caused by inflammation, diet, or external environmental factors.<\/p>\n If doctors can stop the proteins that cause cancer\u00a0and<\/i> stop the bromodomains, they might be able to produce a one-two punch to combat their double hit hypothesis. The treatment would slow BRAF-mutated colorectal cancer growth and encourage natural cancer suppressors.<\/p>\n That idea will be tested in the human trials that were recently approved by the National Cancer Institute. A BRAF-inhibitor, an EGFR-inhibitor, and a bromodomain-inhibitor will be administered to patients. This combined treatment was developed by Kopetz and his colleague Dr. Kunal Rai, an Associate Professor of Genomic Medicine at MD Anderson.<\/p>\n The research moved from the GI Research Foundation-funded mouse models to human trials exceptionally quickly<\/strong>, according to Kopetz.<\/p>\n \u201cIt\u2019s rare for the pieces to come together like this,\u201d he said. \u201cLots of times, this would be two years of work to get the human trials up and running. But we were able to show how clearly this approach worked in multiple mouse models and that really sped things up.\u201d<\/p>\n Other funding from the GI Research Foundation will help speed things up even further. \u201cThe new technologies and techniques that Dr. Kopetz and his team are exploring will give them the ability to innovate that much faster. It provides the entire community with the means to gather high-quality data more quickly and get it into trials and ultimately into the clinic,\u201d said Dr. David Rubin. Rubin is the Joseph B. Kirsner Professor of Medicine and Chief of the Section of Gastroenterology, Hepatology and Nutrition at University of Chicago Medicine. He is also GI Research Foundation\u2019s Senior Scientific Advisor.\u00a0<\/p>\n \u201cThe GI Research Foundation has a legacy of funding high risk-high reward and innovative science, and doing so efficiently and extraordinarily effectively. Kopetz and his colleagues were recipients of a dedicated campaign that we launched in 2022 to tackle the most difficult challenges of colorectal cancer.\u201d<\/p>\n \u201cSupport from the GI Research Foundation allows us to accelerate our work and try some out of the box stuff,\u201d Kopetz said. \u201cWe have amazing animal models, but there\u2019s no substitute for understanding cancer and treatments with the patients themselves. We want to develop the tools we need so we can learn as much as possible from them and help them as much and as quickly as we can.\u201d<\/p>\n About the GI Research Foundation<\/strong><\/p>\n The GI Research Foundation was founded in 1961 by grateful patients and friends of the late Dr. Joseph B. Kirsner, a pioneer in gastroenterology who devoted his life to medicine, teaching, and patient care. Today, the University of Chicago Medicine\u2019s Digestive Diseases Center, which is supported by the foundation, is internationally recognized for research-driven medicine and its team of highly specialized physicians. For more information, see:\u00a0https:\/\/giresearchfoundation.org\/<\/a><\/p>\n About the University of Chicago Digestive Diseases Center<\/strong><\/p>\n The Digestive Diseases Center at the University of Chicago Medicine is a collaborative, multidisciplinary network of physicians, researchers and affiliated health professionals who share a legacy of innovation and a common purpose: to improve the lives of patients who suffer from digestive diseases. For more information, see:\u00a0https:\/\/www.uchicagomedicine.org\/conditions-services\/digestive-diseases<\/a><\/p>\n Contact Information:<\/strong><\/p>\n <\/p>\n Jackie Casey <\/p>\n Executive Director <\/p>\n
\n\n Jackie Casey
\n\n Executive Director
\n \n jcasey@girf.org<\/a>\n
\n \n 312-332-1350
\n \n\n \n \n \n \n
\n Original Source:\n \n Research for the Treatment of a 'Black Sheep' Cancer Moves to Human Clinical Trials <\/a>\n\n \n \n ","protected":false},"excerpt":{"rendered":"
\n CHICAGO, December 13, 2023 (Newswire.com)
\n –
\n <\/strong>Many cancers caused by the mutation of the BRAF gene respond well to a class of immunotherapies known as BRAF-inhibitors. BRAF-mutated colorectal cancer, however, almost never does. Doctors have known this for years, but they are yet to find a treatment that works well for most patients.<\/p>\n